• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » The CenterWatch Weekly, November 14, 2016

The CenterWatch Weekly, November 14, 2016

November 14, 2016
CenterWatch Staff

Litmus Health refocuses trials on quality of life and efficacy

Beta-testing has begun for Litmus Health, a data-capture platform that aims to integrate personal, home-based and wearable technology into clinical trials. Litmus brought together healthcare, bioinformatics and software development experts to create a unique platform with which to guide trial management. Dr. Samuel Volchenboum, chief science of­ficer of Litmus Health and director of the Center for Research Informatics at the University of Chicago, said, “Litmus Health is enabling [the use of] wearables and mobile devices alongside traditional metrics to demonstrate the feasibility of the platform and to show how passive data collection can add value to traditional metrics.”

Bridge Medicines launches as a reimagining of the drug discovery path

Memorial Sloan Kettering Cancer Center (MSKCC), The Rockefeller University and Weill Cornell Medicine have formed a new drug discovery company called Bridge Medicines. The three New York City academic institu­tions have launched the new company in partnership with Takeda Pharmaceutical, and healthcare investment firms Bay City Capital of San Francisco and Deerfield Management of New York City, and say it will complete “a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.”

 

To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing